Evidence map›Paper›PMID 21844889›Full record

SynthesisProstate cancer and prostatic diseases2012

18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.

G Bauman, T Belhocine, M Kovacs, A Ward, M Beheshti, I Rachinsky

2 registry-linked trialsAbstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Prostate cancer and prostatic diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02855190 naunknown statusnot on this mapstarted 2016, after this paper: background citation

Pilot Comparative Study of PET/MR and PET/CT With Different Tracers (18F-FDG and 68Gallium Citrate) in the Diagnosis of Periprosthetic Joint Infection

TypeinterventionalSponsorChang Gung Memorial HospitalRan2016 to 2018Enrolled30ConditionsInfection and Inflammatory Reaction Due to Internal Joint ProsthesisArms68Ga-citrate and 18F-FDG PET scans
NCT05622162 phase3unknown statusnot on this mapstarted 2022, after this paper: background citation

Phase III Multicentre Prospective Comparative Study of Detection Rate of 18F-JK-PSMA-7 and of 18F-fluorocholine in Patients With Biochemical Recurrence of Prostate Cancer After Previous Treatment With Curative Intent

TypeinterventionalSponsorITEL Telecomunicazioni SrlRan2022 to 2024Enrolled106ConditionsProstate Cancer, 18F- Fluorocholine, PSMA PET, RadiotherapyArmsRadiopharmaceutical 18F-JK-PSMA-7, Radiopharmaceutical 18F-Fluorocholine
3 · Its place in the literature

Who cites it

58 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014
    Trial
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. SimultaneousFrontiers in oncology · 2018
    Article
  17. QuantitativeEJNMMI research · 2017
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

G BaumanDepartment of Oncology, The University of Western Ontario, London Health Sciences Centre-St Joseph's Healthcare Centre, London, Ontario, Canada. Glenn.bauman@lhsc.on.ca
T Belhocine
M Kovacs
A Ward
M Beheshti
I Rachinsky

Funding

Canadian Institutes of Health Research CTP 87515
6 · The paper itself

Abstract

backgroundPositron emission tomography (PET or combined PET-computed tomography (PET/CT)) allows the non-invasive interrogation of metabolic processes using radiolabeled probes. Altered choline metabolism has been noted as a characteristic of prostate cancer (PCa), and radiolabeled choline and choline analogs have been investigated as PET/CT imaging agents for prostate cancer; [(18)F]fluoromethyl-dimethyl-2-hydroxyethyl-ammonium ((18)F-FCH) shows particular promise as a PCa imaging agent given its favorable physical and pharmacokinetic properties.

methodsWe conducted a systematic review of results to date with (18)F-FCH. As the tracer was first described by DeGrado in 2001, we limited our search from January 2001 to August 2011.

resultsIn all, 37 studies including 1244 patients met the inclusion criteria. Studies included those detailing the radiosynthesis of (18)F-FCH, preclinical and early clinical dosimetry, and biodistribution (n=7); evaluation of local disease (n=6), nodal disease (n=5), bone metastases and castrate-resistant disease (n=7), biochemical recurrence (n=11), radiotherapy planning (n=7) and sources of false-positive studies (n=2); and some studies reported on multiple indications. Potential sources of variations in the studies affecting reported performance included case series size, variation in extent of disease at imaging (including Gleason grade, and PSA), selection of gold standards for comparison and variations in scan technique.

conclusionsOn the basis of the review, we suggest potential scenarios where this metabolic imaging might be considered for further evaluation in clinical trials for guiding PCa management.

Indexed as

RadiopharmaceuticalsCholineHumansLymphatic MetastasisMaleMultimodal ImagingNeoplasm Recurrence, LocalNeoplasm StagingOrchiectomyPositron-Emission TomographyProstatic NeoplasmsRadiation DosageTissue DistributionTomography, X-Ray ComputedCholinefluorocholineRadiopharmaceuticals

Identifiers

PMID21844889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.